FDA — authorised 22 April 1968
- Marketing authorisation holder: WYETH AYERST
- Status: approved
🇺🇸 Pathocil in United States
FDA authorised Pathocil on 22 April 1968
Marketing authorisations
FDA — authorised 22 April 1968
- Application: NDA050092
- Marketing authorisation holder: WYETH AYERST
- Local brand name: PATHOCIL
- Indication: FOR SUSPENSION — ORAL
- Status: approved
FDA — authorised 9 May 1968
- Application: NDA050011
- Marketing authorisation holder: WYETH AYERST
- Local brand name: PATHOCIL
- Indication: CAPSULE — ORAL
- Status: approved
Pathocil in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Pathocil approved in United States?
Yes. FDA authorised it on 22 April 1968; FDA authorised it on 22 April 1968; FDA authorised it on 9 May 1968.
Who is the marketing authorisation holder for Pathocil in United States?
WYETH AYERST holds the US marketing authorisation.